

# Oral Presentation Program

Session	Date and Time	Room	Chair	Category	Presentation Number	Speaker	Title	
Oral Presentation 1	November 29 (Wed.) 9:30-10:30	Room D 2F Heian	Hiroaki Yuasa Yoshiharu Deguchi	Transporter	01-1	Yoshihide Yamanashi	Lipoproteins act as drug carriers and regulate pharmacokinetics of lipoprotein-associated drugs	
					01-2	Kumiko Ueda	Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells	
					01-3	Yasuo Uchida	Blood-brain barrier P-glycoprotein activation strategy as a new therapy of brain infarct	
					01-4	Yuta Yagi	Proteomics based characterization of the blood-spinal cord barrier transporters in rats: Comparison with the blood-brain barrier	
	November 29 (Wed.) 10:30-11:18	Room D 2F Heian	Takuo Ogihara Takashi Okura	Transporter	01-5	Ryohei Goto	OUTER blood-CSF barrier (arachnoid membrane) abundantly expresses OAT1, OAT3, PEPT2 and BCRP proteins as compared to INNER blood-CSF barrier (choroid plexus)	
					01-6	Yamato Sano	Analysis of Blood-Brain Barrier Drug Transport using Oatp1a4-Humanized Mouse	
					01-7	Saki Noguchi	Transcriptional regulatory element for OAT4 (SLC22A11) gene in human placental choriocarcinoma JEG-3 cells	
					01-8	Fan Zhang	The intrinsic adaptive response of intrahepatic cholestasis induced by 17 $\alpha$ -ethynylestradiol in rats: Increasing hepatic biosynthetic ratio of chenodeoxycholic acid and bile acids urinary excretion	
November 29 (Wed.) 10:30-11:18	Room E 2F Zuiun	Tomohiro Terada Tomohiro Nabekura	Drug interaction	01-9	Atsuko Tomaru	Physiologically Based Pharmacokinetic (PBPK) Analysis of Nonlinear Pharmacokinetics of Maraviroc		
				Absorption	02-1	Takumi Tomono	Snail-induced Epithelial to Mesenchymal Transition Activates P-gp via increasing the Scaffolding Protein Moesin	
					02-2	Itsuki Todokoro	Effect of Epithelial-Mesenchymal Transition Induced by Snail on Efflux Transporters	
				02-3	Chiaki Okabe	The organ-specific regulation of BCRP and P-gp		
Oral Presentation 2	November 29 (Wed.) 9:30-10:30	Room E 2F Zuiun	Junya Nagai Yukio Kato	Transporter	02-4	Toshiki Kurosawa	Gene expression and function of drug transporters in brain microvascular endothelial cells derived from human iPS cells	
					02-5	Kaho Suzuki	Comparative Evaluation of the Functions of PCFT and ASBT in Enterocyte-Like Cells Differentiated from Human iPS Cells	
					Drug interaction	02-6	Takeshi Miyake	Investigation of endogenous substrates as surrogate biomarker for drug interaction studies involving OCT2
						02-7	Shizuka Hozuki	A new integration method of <i>in vitro</i> and <i>in vivo</i> information for systematic prediction of drug-drug interactions caused by inhibitions of multiple CYP species
	November 29 (Wed.) 10:30-11:18	Room E 2F Zuiun	Tomohiro Terada Tomohiro Nabekura	Absorption	02-8	Yuuki Kaneko	Cyclosporine A-loaded nanoparticles with modification of surface properties for the pharmacokinetic control	
					02-9	Shimul Halder	Enhanced Biopharmaceutical Characteristics of Megestrol Acetate with Reduced Food Effect Employing Self-micellizing Solid Dispersion Approach	
					Pharmacokinetics	03-1	Kazutaka Sekiguchi	Quantitative prediction of pharmacokinetic profiles of S-777469 and its sequential metabolites in human using humanized-liver mice and whole-body PBPK model
						03-2	Takashi Yoshikado	Construction of a physiologically-based pharmacokinetic model for coproporphyrin I, an endogenous probe for hepatic organic anion transporting polypeptides (OATPs)
Oral Presentation 3	November 29 (Wed.) 9:30-10:18	Room F 2F Hourai	Kiyomi Ito Toshiyuki Sakaeda	Pharmacokinetics	03-3	Kota Toshimoto	Proposal of a PBPK model of Glycochenodeoxycholate-3-sulfate (GCDCA-S) as an endogenous biomarker	
					03-4	Nora Lee	Physiologically Based Pharmacokinetic Analyses of Nonlinear Pharmacokinetics of Taxanes	
					Pharmacokinetics	03-5	Takahito Furuya	Identification of D-luciferin transporters and their application for <i>in vivo</i> bioluminescence imaging
						03-6	Kotaro Itohara	Population pharmacokinetics and pharmacodynamics of trichloroethanol in pediatric patients
	November 29 (Wed.) 10:18-11:06	Room F 2F Hourai	Naoki Ishiguro Fumiyoshi Yamashita	Pharmacokinetics	03-7	Kazutaka Oda	Optimization of vancomycin dose by Bayesian estimation-based TDM in patients with continuous renal replacement therapy	
					03-8	Ryota Tsukada	Eudragit <sup>®</sup> RS/RL-based sustained-release formulation for pharmacokinetic control	
					Drug delivery	04-1	Seiya Hiranaka	Brain-targeting drug delivery system: Molecular design and functional assessment of hybrid compound composed of histone deacetylase inhibitor and pyrrolamine
						04-2	Hidemasa Katsumi	Development of serine-modified polyamidoamine dendrimer as a novel renal targeting carrier
Oral Presentation 4	November 29 (Wed.) 15:00-16:00	Room D 2F Heian	Teruko Imai Atsushi Yonezawa	Drug delivery	04-3	Shugo Yamashita	Development of aspartic acid-modified dendrimer-based micelle as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis	
					04-4	Ryo Tonami	Development of a respirable powder formulation of celecoxib for treatment of inflammatory lung diseases	
					04-5	Satoshi Hirano	Development of label free comprehensive absolute quantification method by SWATH-MS combined with <i>in silico</i> peptide selection criteria: Its application for the hepatic drug delivery	
					Toxicity	04-6	Rika Harabayashi	Role of activating transcription factor 3 in drug-induced epithelial-mesenchymal transition in cultured human alveolar epithelial cells
	04-7	Carsten Ehrhardt	Nucleophilic substitution reactions of ergothioneine might be a novel xenobiotic deactivation mechanism					
	04-8	Yanrong Ma	Alterations of renal excretion pathways in gentamicin-induced renal injury in rat					
	04-9	Guoqiang Zhang	Perturbation of bile acid homeostasis caused by altered transporters and enzymes expression is an early pathogenesis event of isoniazid induced liver injury in rats					
	Oral Presentation 5	November 29 (Wed.) 15:00-16:00	Room E 2F Zuiun	Masahiro Iwaki Katsuhisa Inoue	Drug delivery	05-1	Yosuke Iyama	Pharmacokinetic and safety assessments of transdermally administered raloxifene
05-2						Kosuke Sakai	Development of macromolecular hydrogen sulfide donor using serum albumin for the treatment of reactive oxygen species-mediated diseases	
05-3						Chihiro Naito	Efficient transdermal delivery of hPTH <sub>1-34</sub> using hyaluronic acid-microneedle arrays for the treatment of osteoporosis	
05-4						Akiko Tanaka	Transnasal delivery of peptide agonist specific to neuromedin U receptor 2 to the brain for the treatment of obesity	
November 29 (Wed.) 16:00-16:48		Room E 2F Zuiun	Kiyoshi Nagata Yuji Ishii	Regulation	05-5	Daisuke Inoue	Direct delivery of CNS drugs to the brain by nasal application III: Pharmacokinetic analysis of the effect of glymphatic system on drug delivery to brain parenchyma	
					05-6	Shinsaku Tokumitsu	Post-transcriptional regulation of human AADAC by miR-222-3p	
					05-7	Yuya Ohtsuki	Exploration of compounds that inhibit Cytochrome P450 3A protein degradation	
					05-8	Amira Abdel-Daim	Applications of fluorophosphonate biotin probe in qualitative and quantitative analysis of serine hydrolases	
Oral Presentation 6	November 30 (Thu.) 9:30-10:30	Room D 2F Heian	Ikuko Yano Tatsuhiko Tachibana	Pharmacokinetics	05-9	Eiji Hishinuma	Functional characterization of 21 allelic variants of dihydropyrimidinase	
					06-1	Masashi Ishiguro	Determination of mizoribine, an immunosuppressant, and mizoribine-5' -monophosphate, an active metabolite, in peripheral blood mononuclear cells of kidney transplantation recipients	
					06-2	Ryo Fujino	IVIVE of the Hepatic Intrinsic Clearance of Antidiabetic Drugs Based on an Extended Clearance Concept with Considering the Effect of Albumin on Their Hepatic Uptake and Metabolism	
					06-3	Seiji Miyauchi	Construction of PBPK model for unconjugated/conjugated bilirubin, a biomarker for the functions of hepatic uptake transporters (OATPs) and biliary excretion transporter (MRP2)	
	November 30 (Thu.) 10:30-11:06	Room D 2F Heian	Yoshiyuki Kubo	Transporter	06-4	Toshimichi Nakamura	Prospective prediction of the clinical trial of tamoxifen: application of a virtual clinical study	
					06-5	Atsushi Yonezawa	PK/PD analysis of rituximab in the patient with non-Hodgkin's lymphoma	
					06-6	Yoshinobu Nakamura	The role of Oatp2a1/Slco2a1 in PGE <sub>2</sub> disposition in the brain of LPS-injected mice	
					06-7	Yosuke Hishikawa	Functional characterization of a carrier-mediated ATP transport system in Caco-2 cells	
November 30 (Thu.) 10:06-10:42	Room E 2F Zuiun	Satomi Onoue	Absorption	06-8	QIN Hong-yan	Down-regulated Fxr-Fgf15 loop of gut-liver axis in the pathogenesis of colitis-related cholestasis in rats		
				Drug interaction	07-1	Hiroshi Arakawa	Bile duct obstruction leads to reduce gastrointestinal absorption of imatinib in mice	
		Masatoshi Tomi	Drug discovery		07-2	Katsumi Iga	Drug-drug interaction produced by theophylline and erythromycin: possibility of hepatic transporter involvement	
				Toxicity	07-3	Hiroshi Sato	Noticeable induction of intestinal Cyp3a via vitamin D receptor in rats breed with vitamin D free diet	
07-4	Ikuko Tsukamoto	COA-CI prevents transforming growth factor- $\beta$ 1-induced epithelial-mesenchymal transition in alveolar epithelial RLE/Abca3 cells						
07-5	Hiroaki Shimada	Alteration of 15-PGDH and OATP2A1 expression regulates hepatic levels of prostaglandin E <sub>2</sub> in liver injury						
07-6	Kazuo Takayama	Generation of human iPS cell-derived hepatocyte-like cells under the chemically defined condition for pharmaceutical research						